Table 2.
Clinical and pathological characteristics of study cohort depending on the presence of biochemical recurrence.
| No recurrence | Recurrence | P | |
|---|---|---|---|
| Number of patients, (%) | 173 (70.9) | 71 (29.1) | |
| Age (years), mean ± std, IQR | 66.3 ± 6.56, 9 | 65.9 ± 6.36, 11 | 0.527† |
| PSA (ng/mL), mean ± std, IQR | 8.37 ± 3.23, 4.29 | 9.99 ± 4.35, 5.20 | 0.005†∗ |
| PSA density (ng/mL2), mean ± std, IQR | 0.29 ± 0.25, 0.18 | 0.46 ± 0.57, 0.27 | 0.002†∗ |
| Preoperative Gleason score, n (%) | 0.015‡∗ | ||
| ≤6 | 71 (41.0) | 16 (22.5) | |
| 7 | 79 (45.7) | 39 (54.9) | |
| ≥8 | 23 (13.3) | 16 (22.5) | |
| Pathological Gleason score, n (%) | 0.423‡ | ||
| ≤6 | 65 (37.6) | 21 (29.6) | |
| 7 | 78 (45.1) | 34 (47.9) | |
| ≥8 | 30 (17.3) | 16 (22.5) | |
| Clinical stage, n (%) | 0.201‡ | ||
| T1c | 134 (77.5) | 47 (66.2) | |
| T2a | 29 (16.8) | 16 (22.5) | |
| T2b | 8 (4.6) | 8 (11.3) | |
| T2c | 2 (1.2) | 0 (0) | |
| Pathological stage, n (%) | 0.001‡∗ | ||
| T2a | 19 (11.0) | 6 (8.45) | |
| T2b | 7 (4.05) | 1 (1.41) | |
| T2c | 104 (60.1) | 38 (53.5) | |
| T3a | 36 (20.8) | 11 (15.5) | |
| T3b | 7 (4.05) | 15 (21.1) | |
| Extracapsular disease, n (%) | 0.064‡ | ||
| No | 130 (75.1) | 45 (63.4) | |
| Yes | 43 (24.9) | 26 (36.6) | |
| Surgical margins, n (%) | 0.021‡∗ | ||
| Negative | 126 (72.8) | 41 (57.7) | |
| Positive | 47 (27.2) | 30 (42.3) | |
| Seminal vesicles invasion, n (%) | <0.001‡∗ | ||
| No | 166 (96.0) | 56 (78.9) | |
| Yes | 7 (4.05) | 15 (21.1) | |
| Lymph nodes invasion, n (%) | <0.001‡∗ | ||
| No | 83 (100.0) | 39 (55.7) | |
| Yes | 0 (0) | 31 (44.3) |
†Mann-Whitney U test, ‡chi-square test, *statistically significant, std: standard deviation, and IQR: interquartile range.